Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile

ACS Infectious Diseases

Volumn 3, Issue 5, 2017, Pages 349-359

  Duvall, Jeremy R ^a   Bedard, Leanne ^b   Naylor Olsen, Adel M ^b   Manson, Abigail L ^a   Bittker, Joshua A ^a   Sun, Wenye ^c   Fitzgerald, Mark E ^a   He, Zhenmin ^c   Lee, Maurice D ^a   Marie, Jean Charles ^a   Muncipinto, Giovanni ^a   Rush, Diane ^b   Xu, Deming ^c   Xu, Huisheng ^c   Zhang, Mingliang ^c   Earl, Ashlee M ^a   Palmer, Michelle A ^a   Foley, Michael A ^a   Vacca, Joseph P ^b   Scherer, Christina A ^a,d  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b WUXI APPTEC   (China)

^c WuXi AppTec ^*  (China)

^d Kanyos Bio Inc   (United States)

Author keywords

C. difficile; CDAD; diversity oriented synthesis; glutamate racemase

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BRD 0761; BRD 3098; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; METRONIDAZOLE; RACEMASE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BRD0761; BRD3098; CARBANILAMIDE DERIVATIVE; FUSED HETEROCYCLIC RINGS; GLUTAMATE RACEMASE; ISOMERASE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; CACO-2 CELL LINE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM PERFRINGENS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; EC90; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS GASSERI; LACTOBACILLUS RHAMNOSUS; MICROBIAL DIVERSITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PEPTONIPHILUS ASACCHAROLYTICUS; PEPTOSTREPTOCOCCUS ANAEROBIUS; PREVOTELLA MELANINOGENICA; PRIORITY JOURNAL; RECURRENCE RISK; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; WHOLE GENOME SEQUENCING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MORTALITY; PATHOLOGY; PSEUDOMEMBRANOUS COLITIS; SPECIES DIFFERENCE; SURVIVAL ANALYSIS; SYNTHESIS;

AMINO ACID ISOMERASES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; DRUG DESIGN; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GENE EXPRESSION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HETEROCYCLIC COMPOUNDS, 2-RING; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PHENYLUREA COMPOUNDS; PYRROLES; QUINOLINES; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL ANALYSIS;

EID: 85019242501     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.6b00206     Document Type: Article

References (38)

1. Lessa, F. C., Mu, Y., Bamberg, W. M., Beldays, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., Wilson, L. E., Winston, L. G., Cohen, J. A., Limbago, B. M., Fridkin, S. K., Gerding, D. N., and L. Clifford McDonald, L. C. (2015) Burden of Clostridium difficile Infection in the United States N. Engl. J. Med. 372, 825-834 10.1056/NEJMoa1408913
2. Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., and Onderdonk, A. B. (1978) Antibiotic-associated Pseudomembranous Colitis due to Toxin-producing Clostridia N. Engl. J. Med. 298, 531-534 10.1056/NEJM197803092981003
3. Cecil, J. A. (2012) Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures Curr. Infect. Dis. Rep. 14, 612-619 10.1007/s11908-012-0298-9
4. Abt, M. C., McKenney, P. T., and Pamer, E. G. (2016) Clostridium difficile colitis: pathogenesis and host defence Nat. Rev. Microbiol. 14, 609-620 10.1038/nrmicro.2016.108
5. Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., Shue, Y. K., and OPT-80-003 Clinical Study Group. (2011) Fidaxomicin versus Vancomycin for Clostridium difficile Infection N. Engl. J. Med. 364, 422-431 10.1056/NEJMoa0910812
6. Khosravi, A. and Mazmanian, S. K. (2013) Disruption of the gut microbiome as a risk factor for microbial infections Curr. Opin. Microbiol. 16, 221-227 10.1016/j.mib.2013.03.009
7. Borody, T. J., Brandt, L. J., Paramsothy, S., and Agrawal, G. (2013) Fecal microbiota tranplantation: a new standard treatment option for Clostridium difficile infection Expert Rev. Anti-Infect. Ther. 11, 447-449 10.1586/eri.13.26
8. Weingarden, A. R., Hamilton, M. J., Sadowsky, M. J., and Khoruts, A. (2013) Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation J. Clin. Gastroenterol. 47, 735-737 10.1097/MCG.0b013e31829004ae
9. Food and Drug Administration, C. f. B. E. a. R. (2013) Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies; U.S. Department of Health and Human Services, Food and Drug Administration: Office of Communication, Outreach and Development, Rockville, MD, USA.
10. Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 6, 29-40 10.1038/nrd2201
11. Dandapani, S. and Marcaurelle, L.A. (2010) Grand challenge commentary: Accessing new chemical space for 'undruggable' targets Nat. Chem. Biol. 6, 861-863 10.1038/nchembio.479
12. Lovering, F., Bikker, J., and Humblet, C. (2009) Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52, 6752-6756 10.1021/jm901241e
13. Lukens, A. K., Heidebrecht, R. W., Jr., Mulrooney, C., Beaudoin, J. A., Comer, E., Duvall, J. R., Fitzgerald, M. E., Masi, D., Galinsky, K., Scherer, C. A., Palmer, M., Munoz, B., Foley, M., Schreiber, S. L., Wiegand, R. C., and Wirth, D. F. (2015) Diversity-Oriented Synthesis Probe Targets Plasmodium falciparum Cytochrome b Ubiquinone Reduction Site and Synergizes With Oxidation Site Inhibitors J. Infect. Dis. 211, 1097-1103 10.1093/infdis/jiu565
14. Kato, N., Comer, E., Sakata-Kato, T., Sharma, A., Sharma, M., Maetani, M., Bastien, J., Brancucci, N. M., Bittker, J. A., Corey, V., Clarke, D., Derbyshire, E. R., Dornan, G., Duffy, S., Eckley, S., Itoe, M. A., Koolen, K. M., Lewis, T. A., Lui, P. S., Lukens, A. K., Lund, E., March, S., Meibalan, E., Meier, B. C., McPhail, J., Mitasev, B., Moss, E. L., Sayes, M., VanGessel, Y., Wawer, M. J., Yoshinaga, T., Zeeman, A. M., Avery, V. M., Bhatia, S. N., Burke, J. E., Catteruccia, F., Clardy, J. C., Clemons, P. A., Dechering, K. J., Duvall, J. R., Foley, M. A., Gusovsky, F., Kocken, C. H., Marti, M., Morningstar, M. L., Munoz, B., Neafsey, D. E., Sharma, A., Winzeler, E. A., Wirth, D. F., Scherer, C. A., and Schreiber, S. L. (2016) Diversity-oriented synthesis yields novel multistage antimalarial inhibitors Nature 2016 (538) 344-349 10.1038/nature19804
15. Carmody, L. C., Germain, A. R., Engel, J. C., Gut, J., Kaiser, M., Jewett, I., LeQuemen, S., Marie, J. C., Dandapani, S., Rodriguez, A., Perez, J. R., McKerrow, J. H., Palmer, M. A., Munoz, B., and Schreiber, S. L. (2010) Identification of Diversity-Oriented Synthesis Derived Small Molecule, ML341, with Cidal Activity Against Trypanosoma cruzi. In Probe Reports from the NIH Molecular Libraries Program, PMID: 24479197, Bethesda, MD, USA.
16. Hardesty, J. S. and Juang, P. (2011) Fidaxomicin: A Macrocyclic Antibiotic for the Treatment of Clostridium difficile Infection Pharmacotherapy 31, 877-886 10.1592/phco.31.9.877
17. Chen, X., Katchar, K., Goldsmith, J. D., Nanthakumar, N., Cheknis, A., Gerding, D. N., and Kelly, C. P. (2008) A mouse model of Clostridium difficile-associated disease Gastroenterology 135, 1984-1992 10.1053/j.gastro.2008.09.002
18. Gerard, B., O'Shea, M. W., Donckele, E., Kesavan, S., Akella, L. B., Xu, H., Jacobsen, E. N., and Marcaurelle, L. A. (2012) Application of a Catalytic Asymmetric Povarov Reaction using Chiral Ureas to the Synthesis of a Tetrahydroquinoline Library ACS Comb. Sci. 14, 621-630 10.1021/co300098v
19. Akella, L. B. and Marcaurelle, L. A. (2011) Application of a sparse matrix design strategy to the synthesis of DOS libraries ACS Comb. Sci. 13, 357-364 10.1021/co200020j
20. Doublet, P., van Heijenoort, J., Bohin, J. P., and Mengin-Lecreulx, D. (1993) The murI gene of Escherichia coli is an essential gene that encodes a glutamate racemase activity J. Bacteriol. 175, 2970-2979 PMCID: PMC204615. 10.1128/jb.175.10.2970-2979.1993
21. Fisher, S. L. (2008) Glutamate racemase as a target for drug discovery Microb. Biotechnol. 1, 345-360 10.1111/j.1751-7915.2008.00031
22. Geng, B., Basarab, G., Comita-Prevoir, J., Gowravaram, M., Hill, P., Kiely, A., Loch, J., Macpherson, L., Morningstar, M., Mullen, G., Osimboni, E., Satz, A., Eyermann, C., and Lundqvist, T. (2009) Potent and Selective Inhibitors of Helicobactor pylori Glutamate Racemase (MurI): Pyridodiazepine Amines Bioorg. Med. Chem. Lett. 19, 930-936 10.1016/j.bmcl.2008.11.113
23. Lundqvist, T., Fisher, S. L., Kern, G., Folmer, R. H. A., Xue, Y., Newton, D. T., Keating, T. A., Alm, R. A., and de Jonge, B. L. M. (2007) Exploitation of structural and regulatory diversity in glutamate racemases Nature 447, 817-822 10.1038/nature05689
24. Geng, B., Blodgett, A., Breault, G., Comita-Prevoir, J., Doig, P., and Eyermann, C. J., et al., (2007) Hit to lead studies: exploring 9-benzyl purines as inhibitors of glutamate racemase (MurI) in Gram-positive bacteria. In Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract F1-337, American Society for Microbiology, Chicago, IL, USA.
25. Prosser, G. A., Rodenburg, A., Khoury, H., de Chiara, C., Howell, S., Snijders, A. P., and de Carvalho, L. P. S. (2016) Glutamate racemase is the primary target of β-Chloro- d -alanine in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 60, 6091-6099 10.1128/AAC.01249-16
26. Goldstein, E. J. and Citron, D. M. (2013) Comparative in vitro Activity of SMT19969, a New Antimicrobial Agent, Against Clostridium difficile and 203 Gram-postivie Aerobic and Anaerobic Gut Flora Isolates. In Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract F-624, American Society for Microbiology: Denver, CO, USA.
27. Sattar, A., Thommes, P., Payne, L., Warn, P., and Vickers, R. J. (2015) SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI J. Antimicrob. Chemother. 70, 1757-1762 10.1093/jac/dkv005
28. Mulrooney, C. A., Lahr, D. L., Quintin, M. J., Youngsaye, W., Moccia, D., Asiedu, J. K., Mulligan, E. L., Akella, L. B., Marcaurelle, L. A., Montgomery, P., Bittker, J. A., Clemons, P. A., Brudz, S., Dandapani, S., Duvall, J. R., Tolliday, N. J., and De Souza, A. (2013) An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries J. Comput.-Aided Mol. Des. 27, 455-468 10.1007/s10822-013-9641-y
29. CLSI. ((2007) Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, Approved Standard, 7th ed., Clinical and Laboratory Standards Institute: Wayne, PA, USA.
30. Bentley, D. R. et al. 2008, Accurate whole human genome sequencing using reversible terminator chemistry Nature 456, 53-59 10.1038/nature07517
31. Fisher, S., Barry, A., Abreu, J., Minie, B., Nolan, J., Delorey, T. M., Young, G., Fennell, T. J., Allen, A., Ambrogio, L., Berlin, A. M., Blumenstiel, B., Cibulskis, K., Friedrich, D., Johnson, R., Juhn, F., Reilly, B., Shammas, R., Stalker, J., Sykes, S. M., Thompson, J., Walsh, J., Zimmer, A., Zwirko, Z., Gabriel, S., Nicol, R., and Nusbaum, C. (2011) A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries Genome Biol. 12, R1 10.1186/gb-2011-12-1-r1
32. Li, H. and Durbin, R. (2009) Fast and accurate short read alignment with Burrows-Wheeler transform Bioinformatics 24, 1754-1760 10.1093/bioinformatics/btp324
33. Walker, B. J., Abeel, T., Shea, T., Priest, M., Abouelliel, A., Sakthikumar, S., Cuomo, C. A., Zeng, Q., Wortman, J., Young, S. K., and Earl, A. M. (2014) Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement PLoS One 9, e112963 10.1371/journal.pone.0112963
34. (2014) Schrodinger Release 2014-3: Maestro, version 9.9, Schrodinger, LLC, New York, NY, USA.
35. Madden, T. (2002) Chapter 16. The BLAST Sequence Analysis Tool. 2002 (updated 2003 Aug 13]). In The NCBI Handbook (McEntyre, J. and Ostell, J., Eds.) National Center for Biotechnology Information, Bethesda, MD, USA (available from http://www.ncbi.nlm.nih.gov/books/NBK21097/).
36. Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J. F., Honig, B., Shaw, D. E., and Friesner, R. A. (2004) A Hierarchical Approach to All-Atom Protein Loop Prediction Proteins: Struct., Funct., Genet. 55, 351-367 10.1002/prot.10613
37. Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., and Mainz, D. T. (2006) Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes J. Med. Chem. 49, 6177-6196 10.1021/jm051256o
38. Chou, D. H. C., Duvall, J. R., Gerard, B., Liu, H. B., Pandya, B. A., Suh, B. C., Forbeck, E. M., Faloon, P., Wagner, B. K., and Marcaurelle, L. A. (2011) Synthesis of a Novel Suppressor of beta-Cell Apoptosis via Diversity-Oriented Synthesis ACS Med. Chem. Lett. 2, 698-702 10.1021/ml200120m